Promising disease control and survival was achieved with the use of liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) as a frontline treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase 1/2 trial.
Long-term follow-up results from the study were presented in a poster at the virtual 2020 European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer meeting. Read more . . .